Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: A single centre, prospective one-year observational cohort study of the first 100 patients treated.

In Dermatology
by ClinOwl October 27, 2020

Dupilumab (Dupixent®) is the first biologic drug licensed for treatment of adults with atopic dermatitis (AD). Data regarding its long-term real-world effectiveness and tolerability are limited. We report comprehensive outcome […]

U.S. Burden of Skin and Subcutaneous Diseases Increasing

Can dermatology employers require employees to receive the COVID-19 vaccine?

THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

Expression of retinoid receptors in hand eczema.

S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: A single centre, prospective one-year observational cohort study of the first 100 patients treated.